Valuation: MBX Biosciences, Inc.

Market Cap 2.94B 2.55B 2.41B 2.18B 4.09B 282B 4.12B 28.75B 11.06B 143B 11.05B 10.8B 456B P/E 2026 *
-19.4x
P/E 2027 * -15.2x
Enterprise Value 2.43B 2.11B 1.99B 1.8B 3.38B 233B 3.41B 23.76B 9.14B 118B 9.13B 8.93B 377B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MBX Biosciences, Inc.

1 day+2.67%
1 week-3.03%
Current month-0.84%
1 month-10.92%
3 months+56.70%
6 months+118.14%
Current year+93.66%
1 week 58.39
Extreme 58.394
63.02
1 month 58.39
Extreme 58.394
69.94
Current year 26.14
Extreme 26.14
72.64
1 year 9.64
Extreme 9.64
72.64
3 years 4.81
Extreme 4.8069
72.64
5 years 4.81
Extreme 4.8069
72.64
10 years 4.81
Extreme 4.8069
72.64
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-12
Director of Finance/CFO 73 2026-02-28
Chief Tech/Sci/R&D Officer - 2025-06-22
Director TitleAgeSince
Director/Board Member 66 2020-06-30
Director/Board Member 55 2020-06-30
Director/Board Member 69 2022-04-04
Date Insider Type Main position Quantity % Market Cap. Importance
8/4/26 Sell

Chief Technology Officer

-370 0.0008%
8/3/26 Free

Chief Financial Officer

158,000 0.3281%
8/3/26 Free

Chief Executive Officer

402,000 0.8347%
Change 5-day change 1-year change 3-year change Capi.($)
+2.67%-3.03%+461.91% - 2.87B
+0.56%-3.38%-1.83%+8.00% 45.63B
-0.12%-1.19%+343.42%+545.03% 43.96B
+1.51%+4.04%+45.01%+27.38% 43.73B
-2.07%-1.42%+4.28%+72.97% 40.23B
-0.73%-3.06%+9.63%+38.92% 31.86B
-9.49%-11.23% - - 17.4B
+4.21%+5.01%+24.99%+121.62% 16.62B
+1.83%+3.20%+16.49%+32.73% 14.46B
-0.08%-2.81%+79.24%+31.27% 13.04B
Average -0.17%-1.38%+109.24%+109.74% 26.98B
Weighted average by Cap. -0.31%-1.28%+81.11%+130.65%

Financials

2026 *2027 *
Net sales - -
Net income -153M -132M -125M -113M -213M -14.66B -214M -1.49B -575M -7.44B -574M -562M -23.71B -216M -187M -177M -160M -300M -20.69B -302M -2.11B -811M -10.49B -810M -792M -33.46B
Net Debt -511M -442M -418M -379M -711M -48.99B -716M -4.99B -1.92B -24.84B -1.92B -1.88B -79.22B -418M -362M -343M -310M -582M -40.13B -587M -4.09B -1.57B -20.35B -1.57B -1.54B -64.89B
Logo MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.
Employees
63
Date Price Change Volume
26-09-15 US$61.08 +2.67% 652,589
26-09-14 US$59.49 +0.80% 323,679
26-09-11 US$59.02 -3.15% 306,208
26-09-10 US$60.94 -3.13% 457,266
26-09-09 US$62.91 -0.13% 315,690
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
61.08USD
Average target price
88.36USD
Spread / Average Target
+44.67%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!